EGFR and non-small cell lung carcinoma: For instance, the combination of B-Raf inhibitor, dabrafenib (or vemurafenib), and MEK1/2 inhibitor, trametinib (or cobimetinib), for melanoma [29,30] and the combination of EGFR inhibitor and c-Met inhibitor for non-small cell lung cancer [31,32] have shown great improvement in therapeutic efficacy.